首页 > 最新文献

Current Journal of Neurology最新文献

英文 中文
Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus, not receiving any immunosuppressant medication 系统性红斑狼疮患者的进行性多灶性白质脑病,未接受任何免疫抑制药物治疗
Q4 CLINICAL NEUROLOGY Pub Date : 2023-08-08 DOI: 10.18502/cjn.v22i2.13341
Bardiya Ghaderi, Alaleh Vaghefifar, Farideh Darabi, Hajir Sikaroodi
The Article Abstract is not available.
没有文章摘要。 ;
{"title":"Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus, not receiving any immunosuppressant medication","authors":"Bardiya Ghaderi, Alaleh Vaghefifar, Farideh Darabi, Hajir Sikaroodi","doi":"10.18502/cjn.v22i2.13341","DOIUrl":"https://doi.org/10.18502/cjn.v22i2.13341","url":null,"abstract":"
 
 
 
 
 
 
 
 
 
 
 The Article Abstract is not available.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135746504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran 伊朗Chaharmahal和Bakhtiari省多发性硬化症流行病学参数
Q4 CLINICAL NEUROLOGY Pub Date : 2023-08-08 DOI: 10.18502/cjn.v22i2.13337
Mohammad Amin Omrani, Asghar Bayati, Mohammad Ali Sahraian, Sharareh Eskandarieh
Background: Multiple sclerosis (MS) is a neurological disease with a high burden and disability. There are reports of various medications’ side effects on patients with MS. The aim of the study is to determine the characteristics and medicine usage distribution among patients with MS in Chaharmahal and Bakhtiari Province in Iran. Methods: This registry-based cross-sectional study was performed among MS cases in Chaharmahal and Bakhtiari Province. The epidemiological data were collected from the nationwide MS registry of Iran (NMSRI) from 2019 to 2022. The information collected included age, sex, family history, type of MS, age at MS onset and diagnosis, MS symptoms, physical condition, and history of medication use. All tests were performed at a significance level of 0.05 using SPSS software. Results: A total of 416 patients included in this study. Among them, 325 individuals (78%) were women with mean ± standard deviation (SD) of age of 37.35 ± 8.51 years. No significant difference was observed between men and women in terms of age, type of MS disease, family history of MS, and physical condition (P > 0.05). The results showed that the Expanded Disability Status Scale (EDSS) score in female patients (1.41) was different from the EDSS score in male patients (1.77) (P < 0.05). Most of the patients often used interferon beta (IFN-β). Conclusion: The results provided new insight into the epidemiology and medicine patterns of patients with MS in Chaharmahal and Bakhtiari Province. The epidemiological situation of MS in this province is similar to other parts of Iran. Planning according to national programs is suggested for the management and control of MS.
背景:多发性硬化症(MS)是一种高负担、高致残的神经系统疾病。有各种药物对多发性硬化症患者的副作用的报道。本研究的目的是确定伊朗Chaharmahal和Bakhtiari省多发性硬化症患者的特点和药物使用分布。 方法:在Chaharmahal和Bakhtiari省的MS病例中进行了基于登记的横断面研究。流行病学数据收集自2019年至2022年伊朗全国多发性硬化症登记处(NMSRI)。收集的信息包括年龄、性别、家族史、MS类型、MS发病年龄和诊断年龄、MS症状、身体状况和用药史。所有检验采用SPSS软件,显著性水平为0.05。 结果:本研究共纳入416例患者。其中女性325例(78%),平均±标准差(SD)为37.35±8.51岁。男性和女性在年龄、MS疾病类型、MS家族史和身体状况方面无显著差异(P >0.05)。结果显示,女性患者的扩展残疾状态量表(EDSS)得分为1.41分,男性患者的EDSS得分为1.77分(P <0.05)。大多数患者常使用干扰素(IFN-β)。结论:本研究结果为了解查哈尔马哈尔省和巴赫蒂亚里省多发性硬化症患者的流行病学和用药模式提供了新的认识。本省多发性硬化症流行病学情况与伊朗其他地区相似。建议按照国家规划对MS的管理和控制进行规划。
{"title":"Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran","authors":"Mohammad Amin Omrani, Asghar Bayati, Mohammad Ali Sahraian, Sharareh Eskandarieh","doi":"10.18502/cjn.v22i2.13337","DOIUrl":"https://doi.org/10.18502/cjn.v22i2.13337","url":null,"abstract":"Background: Multiple sclerosis (MS) is a neurological disease with a high burden and disability. There are reports of various medications’ side effects on patients with MS. The aim of the study is to determine the characteristics and medicine usage distribution among patients with MS in Chaharmahal and Bakhtiari Province in Iran.&#x0D; Methods: This registry-based cross-sectional study was performed among MS cases in Chaharmahal and Bakhtiari Province. The epidemiological data were collected from the nationwide MS registry of Iran (NMSRI) from 2019 to 2022. The information collected included age, sex, family history, type of MS, age at MS onset and diagnosis, MS symptoms, physical condition, and history of medication use. All tests were performed at a significance level of 0.05 using SPSS software.&#x0D; Results: A total of 416 patients included in this study. Among them, 325 individuals (78%) were women with mean ± standard deviation (SD) of age of 37.35 ± 8.51 years. No significant difference was observed between men and women in terms of age, type of MS disease, family history of MS, and physical condition (P > 0.05). The results showed that the Expanded Disability Status Scale (EDSS) score in female patients (1.41) was different from the EDSS score in male patients (1.77) (P < 0.05). Most of the patients often used interferon beta (IFN-β).&#x0D; Conclusion: The results provided new insight into the epidemiology and medicine patterns of patients with MS in Chaharmahal and Bakhtiari Province. The epidemiological situation of MS in this province is similar to other parts of Iran. Planning according to national programs is suggested for the management and control of MS.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135795068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review. 芬戈莫德交替给药治疗复发缓解型多发性硬化症:一项系统综述
IF 0.7 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13339
Fereshteh Ghadiri, Omid Mirmosayyeb, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Mahsa Ghajarzadeh

Background: Fingolimod is approved in relapsing-remitting multiple sclerosis (RRMS) with the recommended dose of 0.5 mg daily. To tackle possible adverse events, some clinicians may reduce the dose of fingolimod, mainly in the alternate-day form. We systematically reviewed the literature for efficacy measures of this method. Methods: PubMed (Medline®), Web of Science, Embase, Scopus, and the Cochrane Library databases were searched until April 9, 2021. Clinical studies (other than case reports and case series), in English, were included. Then, publications concerning alternate dose fingolimod (including every other day, every two or three days) were selected. Those studies concerning reduced daily dose (any daily dose less than 0.5 mg/day) were excluded to focus on alternate dosing. Results: Four observational studies were included. Data on Ohtani et al. study were limited. Three other studies were of good quality based on the Newcastle-Ottawa Scale. A total of 296 patients on the standard dose were compared to 276 patients on the alternate dosage. The most common reason for switching to the alternate dose was lymphopenia, followed by elevated liver enzymes. Two studies concluded that the alternate dosing could be a safe, yet effective strategy in patients with intolerable adverse effects of daily dose. However, Zecca et al. warned about the high possibility of disease reactivation. Due to the differences in outcome measures of the studies, meta-analysis was not applicable. Conclusion: This systematic review highlights the ambiguity of evidence on safety and efficacy of alternate dosing of fingolimod, encouraging further research on the subject.

背景:芬戈利莫被批准用于复发缓解型多发性硬化症(RRMS),推荐剂量为每天0.5 mg。为了应对可能的不良事件,一些临床医生可能会减少芬戈利莫的剂量,主要是隔日形式。我们系统地回顾了该方法的疗效测量文献。方法:检索PubMed(Medline®)、Web of Science、Embase、Scopus和Cochrane Library数据库,直到2021年4月9日。包括英文的临床研究(病例报告和病例系列除外)。然后,选择关于芬戈利莫替代剂量的出版物(包括每隔一天、每两天或三天)。那些关于减少日剂量(任何低于0.5 mg/天的日剂量)的研究被排除在外,以集中于交替给药。结果:纳入四项观察性研究。Ohtani等人的研究数据有限。根据纽卡斯尔-渥太华量表,其他三项研究质量良好。共有296名服用标准剂量的患者与276名服用替代剂量的患者进行了比较。改用替代剂量的最常见原因是淋巴细胞减少,其次是肝酶升高。两项研究得出结论,对于日剂量不良反应难以忍受的患者,交替给药可能是一种安全而有效的策略。然而,Zecca等人警告说,疾病重新激活的可能性很高。由于研究结果测量的差异,荟萃分析不适用。结论:这篇系统综述强调了芬戈利莫交替给药的安全性和有效性证据的模糊性,鼓励对该主题进行进一步研究。
{"title":"Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review.","authors":"Fereshteh Ghadiri, Omid Mirmosayyeb, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Mahsa Ghajarzadeh","doi":"10.18502/cjn.v22i2.13339","DOIUrl":"10.18502/cjn.v22i2.13339","url":null,"abstract":"<p><p><b>Background:</b> Fingolimod is approved in relapsing-remitting multiple sclerosis (RRMS) with the recommended dose of 0.5 mg daily. To tackle possible adverse events, some clinicians may reduce the dose of fingolimod, mainly in the alternate-day form. We systematically reviewed the literature for efficacy measures of this method. <b>Methods:</b> PubMed (Medline®), Web of Science, Embase, Scopus, and the Cochrane Library databases were searched until April 9, 2021. Clinical studies (other than case reports and case series), in English, were included. Then, publications concerning alternate dose fingolimod (including every other day, every two or three days) were selected. Those studies concerning reduced daily dose (any daily dose less than 0.5 mg/day) were excluded to focus on alternate dosing. <b>Results:</b> Four observational studies were included. Data on Ohtani et al. study were limited. Three other studies were of good quality based on the Newcastle-Ottawa Scale. A total of 296 patients on the standard dose were compared to 276 patients on the alternate dosage. The most common reason for switching to the alternate dose was lymphopenia, followed by elevated liver enzymes. Two studies concluded that the alternate dosing could be a safe, yet effective strategy in patients with intolerable adverse effects of daily dose. However, Zecca et al. warned about the high possibility of disease reactivation. Due to the differences in outcome measures of the studies, meta-analysis was not applicable. <b>Conclusion:</b> This systematic review highlights the ambiguity of evidence on safety and efficacy of alternate dosing of fingolimod, encouraging further research on the subject.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"110-114"},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43823245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with the number of months of delaying in multiple sclerosis diagnosis: Comparison of count regression models. 多发性硬化症诊断延迟月数的相关因素:计数回归模型的比较
IF 0.7 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13330
Abolfazl Hosseinnataj, Roya Nikbakht, Seyed Nouraddin Mousavinasab, Sharareh Eskandarieh, Mohammad Ali Sahraian, Seyed Mohammad Baghbanian

Background: It may take a long time to diagnose multiple sclerosis (MS) since the emergence of primary symptoms. This study aimed to use count regression models to compare their fit and to identify factors affecting delay in the diagnosis of MS. Methods: Data were collected from the Nationwide MS Registry of Iran (NMSRI) for Mazandaran Province, Iran, using census sampling until April 2022. The four models of Poisson regression, negative binomial (NB) regression, zero-inflated Poisson (ZIP) regression, and zero-inflated negative binomial (ZINB) regression were used in this study. Results: In this study on 2894 patients, 74.0% were women, and 8.5% had a family history of MS. The mean ± standard deviation (SD) of the patients' age was 34.96 ± 9.41 years, and the mean delay in diagnosis was 12.32 ± 33.26 months, with a median of 0 (Q1-Q3: 0-9). The NB regression model showed the best performance, and factors, including a history of hospitalization and the year of symptom onset, had significant effects on a delayed diagnosis. Besides, the Expanded Disability Status Scale (EDSS) score was significantly different before and after 2017; it was also associated with sex, type of MS, and history of hospitalization. Conclusion: The mean diagnostic delay and the mean age of MS diagnosis are critical in Mazandaran Province. Patients with MS develop the disease at an early age and are diagnosed with a long delay. The time of symptom onset is a significant factor in the diagnosis of MS, and in recent years, there have been improvements in the diagnostic process.

背景:多发性硬化症(MS)的原发症状出现后,诊断可能需要很长时间。本研究旨在使用计数回归模型来比较其拟合度,并确定影响MS诊断延迟的因素。方法:数据来自伊朗马赞德兰省的伊朗全国MS登记处(NMSRI),使用人口普查抽样至2022年4月。本研究采用泊松回归、负二项(NB)回归、零膨胀泊松(ZIP)回归和零膨胀负二项回归四种模型。结果:在这项针对2894名患者的研究中,74.0%为女性,8.5%有MS家族史。患者年龄的平均±标准差(SD)为34.96±9.41岁,平均延迟诊断为12.32±33.26个月,中位数为0(Q1-Q3:0-9)。NB回归模型显示出最好的表现,包括住院史和症状发作年份在内的因素对延迟诊断有显著影响。此外,扩展残疾状况量表(EDSS)评分在2017年前后存在显著差异;它还与性别、多发性硬化症类型和住院史有关。结论:在马赞德兰省,MS的平均诊断延迟和平均诊断年龄至关重要。多发性硬化症患者在很小的时候就发展成这种疾病,并且诊断延迟很长时间。症状出现的时间是MS诊断的一个重要因素,近年来,诊断过程有所改善。
{"title":"Factors associated with the number of months of delaying in multiple sclerosis diagnosis: Comparison of count regression models.","authors":"Abolfazl Hosseinnataj, Roya Nikbakht, Seyed Nouraddin Mousavinasab, Sharareh Eskandarieh, Mohammad Ali Sahraian, Seyed Mohammad Baghbanian","doi":"10.18502/cjn.v22i2.13330","DOIUrl":"10.18502/cjn.v22i2.13330","url":null,"abstract":"<p><p><b>Background:</b> It may take a long time to diagnose multiple sclerosis (MS) since the emergence of primary symptoms. This study aimed to use count regression models to compare their fit and to identify factors affecting delay in the diagnosis of MS. <b>Methods:</b> Data were collected from the Nationwide MS Registry of Iran (NMSRI) for Mazandaran Province, Iran, using census sampling until April 2022. The four models of Poisson regression, negative binomial (NB) regression, zero-inflated Poisson (ZIP) regression, and zero-inflated negative binomial (ZINB) regression were used in this study. <b>Results:</b> In this study on 2894 patients, 74.0% were women, and 8.5% had a family history of MS. The mean ± standard deviation (SD) of the patients' age was 34.96 ± 9.41 years, and the mean delay in diagnosis was 12.32 ± 33.26 months, with a median of 0 (Q1-Q3: 0-9). The NB regression model showed the best performance, and factors, including a history of hospitalization and the year of symptom onset, had significant effects on a delayed diagnosis. Besides, the Expanded Disability Status Scale (EDSS) score was significantly different before and after 2017; it was also associated with sex, type of MS, and history of hospitalization. <b>Conclusion:</b> The mean diagnostic delay and the mean age of MS diagnosis are critical in Mazandaran Province. Patients with MS develop the disease at an early age and are diagnosed with a long delay. The time of symptom onset is a significant factor in the diagnosis of MS, and in recent years, there have been improvements in the diagnostic process.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"65-71"},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46736067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Eculizumab治疗视神经脊髓炎谱系障碍
IF 0.7 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13342
Fardin Nabizadeh, Abdorreza Naser Moghadasi
The Article Abstract is not available.
文章摘要不可用。
{"title":"Eculizumab in the treatment of neuromyelitis optica spectrum disorder.","authors":"Fardin Nabizadeh, Abdorreza Naser Moghadasi","doi":"10.18502/cjn.v22i2.13342","DOIUrl":"10.18502/cjn.v22i2.13342","url":null,"abstract":"The Article Abstract is not available.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"140-143"},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47968002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study. COVID-19大流行期间多发性硬化症患者对再感染、复发和焦虑的恐惧:一项多中心研究
IF 0.7 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13332
Abdorreza Naser Moghadasi, Saeed Vaheb, Sara Hamtaei-Ghashti, Aysa Shaygannejad, Mozhdeh Askari, Vahid Shaygannejad, Mohmmad Ali Sahraian, Mahsa Ghajarzadeh

Background: Fear of relapse and re-infection during the coronavirus disease 2019 (COVID-19) pandemic can affect people with chronic relapsing diseases, such as multiple sclerosis (MS). We evaluated fear of re-infection, anxiety, and relapse during the COVID-19 pandemic in Iranian people with MS. Methods: This multicenter, cross-sectional study was performed in the MS clinic of Sina Hospital, Tehran, Iran, and Hakim Private Hospital, Isfahan, Iran, between January and April 2022. We asked the participants to fill out validated Persian versions of Fear of Relapse Scale (FoR), and Beck Anxiety Inventory (BAI) questionnaires and answer a binary question about their fear of getting reinfected with COVID-19. Results were reported as mean ± standard deviation (SD) for continuous variables or frequencies for categorical variables. For continuous variables which did not have a normal distribution, we reported the median and interquartile range (IQR). Spearman correlation coefficient between anxiety score and FoR score was calculated. An independent samples t-test was used to compare continuous variables. Results: Three hundred and sixty-eight patients participated in this study. The median scores of FoR and BAI were 49.7 and 34.3, respectively. Fifty-three had new relapses in their last infection. Thirty-six percent of the patients had a fear of getting COVID-19 again, and 43% had a fear of relapse during infection. Three hundred and twenty-three had two doses of COVID-19 vaccine; the most frequent type of vaccine was Sinopharm. There was a significant difference between the median FoR scores among patients with and without relapse during the last COVID-19. There was also a significant positive correlation between anxiety score and FoR (r = 0.49, P < 0.001). Conclusion: More than one-third of enrolled cases had fear of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) re-infection. Patients who experienced exacerbation of symptoms even in the form of relapse or pseudo relapse (possible clinical relapse) had a higher fear of infection.

背景:在2019冠状病毒病(COVID-19)大流行期间,对复发和再感染的恐惧可能会影响多发性硬化症(MS)等慢性复发性疾病患者。我们评估了2019冠状病毒病大流行期间伊朗多发性硬化症患者对再感染、焦虑和复发的恐惧。方法:这项多中心横断面研究于2022年1月至4月在伊朗德黑兰Sina医院和伊斯法罕Hakim私立医院的多发性硬化症诊所进行。我们要求参与者填写波斯语版本的恐惧复发量表(FoR)和贝克焦虑量表(BAI)问卷,并回答一个关于他们害怕再次感染COVID-19的二元问题。结果以连续变量的平均值±标准差(SD)或分类变量的频率报告。对于不具有正态分布的连续变量,我们报告了中位数和四分位数范围(IQR)。计算焦虑评分与FoR评分之间的Spearman相关系数。采用独立样本t检验比较连续变量。结果:368例患者参与了本研究。FoR和BAI的中位数分别为49.7分和34.3分。53例在最后一次感染中有新的复发。36%的患者担心再次感染COVID-19, 43%的患者担心感染期间复发。323人接种了两剂COVID-19疫苗;最常见的疫苗类型是国药控股。在最后一次COVID-19期间复发和未复发患者的中位数评分之间存在显着差异。焦虑评分与FoR也有显著正相关(r = 0.49, P < 0.001)。结论:超过三分之一的病例对SARS-CoV-2再次感染有恐惧。经历症状加重甚至复发或假性复发(可能的临床复发)的患者对感染有更高的恐惧。
{"title":"Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study.","authors":"Abdorreza Naser Moghadasi, Saeed Vaheb, Sara Hamtaei-Ghashti, Aysa Shaygannejad, Mozhdeh Askari, Vahid Shaygannejad, Mohmmad Ali Sahraian, Mahsa Ghajarzadeh","doi":"10.18502/cjn.v22i2.13332","DOIUrl":"10.18502/cjn.v22i2.13332","url":null,"abstract":"<p><p><b>Background:</b> Fear of relapse and re-infection during the coronavirus disease 2019 (COVID-19) pandemic can affect people with chronic relapsing diseases, such as multiple sclerosis (MS). We evaluated fear of re-infection, anxiety, and relapse during the COVID-19 pandemic in Iranian people with MS. <b>Methods:</b> This multicenter, cross-sectional study was performed in the MS clinic of Sina Hospital, Tehran, Iran, and Hakim Private Hospital, Isfahan, Iran, between January and April 2022. We asked the participants to fill out validated Persian versions of Fear of Relapse Scale (FoR), and Beck Anxiety Inventory (BAI) questionnaires and answer a binary question about their fear of getting reinfected with COVID-19. Results were reported as mean ± standard deviation (SD) for continuous variables or frequencies for categorical variables. For continuous variables which did not have a normal distribution, we reported the median and interquartile range (IQR). Spearman correlation coefficient between anxiety score and FoR score was calculated. An independent samples t-test was used to compare continuous variables. <b>Results:</b> Three hundred and sixty-eight patients participated in this study. The median scores of FoR and BAI were 49.7 and 34.3, respectively. Fifty-three had new relapses in their last infection. Thirty-six percent of the patients had a fear of getting COVID-19 again, and 43% had a fear of relapse during infection. Three hundred and twenty-three had two doses of COVID-19 vaccine; the most frequent type of vaccine was Sinopharm. There was a significant difference between the median FoR scores among patients with and without relapse during the last COVID-19. There was also a significant positive correlation between anxiety score and FoR (r = 0.49, P < 0.001). <b>Conclusion:</b> More than one-third of enrolled cases had fear of severe acute respiratory syndrome coronavirus 2 <b>(</b>SARS-CoV-2) re-infection. Patients who experienced exacerbation of symptoms even in the form of relapse or pseudo relapse (possible clinical relapse) had a higher fear of infection.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"82-86"},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68126479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports. 醋酸格拉替默和干扰素β -1a在多发性硬化症患者中的不良副作用:对病例报告的系统回顾
IF 0.7 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13340
Mohsen Rastkar, Mahsa Ghajarzadeh, Mohammad Ali Sahraian

Background: Glatiramer acetate (GA) and Interferon (IFN) beta-1a are used as first-line disease-modifying treatments for multiple sclerosis (MS). In this systematic review, we summarized case reports and case series of adverse side effects of GA and IFN beta-1a in MS patients. Methods: Without any restrictions, PubMed, Scopus, Web of Sciences, and Embase databases, and gray literature were systemically searched until June 2022. Articles were screened and data were extracted based on a predefined table by two independent reviewers. The risk of bias was assessed using the Joanna Briggs Institute (JBI) tool. Results: We identified 2103 records from the preliminary search. After deduplication and screening, 172 articles were included in the systematic review. In total, 229 individuals (52 men, 173 women, and 4 unknown) were included in the study. The most common adverse events were cutaneous (32.75%), hepatic (13.54%), allergic (8.3%), and neurological (5.68%) side effects. Furthermore, most reported side effects were related to autoimmune diseases or hypersensitivity reactions. Conclusion: GA and IFN beta-1a are associated with several side effects which may be related to the immunomodulatory function of medication or other injection-related reactions.

背景:醋酸格拉替默(GA)和干扰素(IFN) β -1a被用作多发性硬化症(MS)的一线疾病改善治疗。在这篇系统综述中,我们总结了GA和IFN β -1a在MS患者中的不良反应的病例报告和病例系列。方法:在没有任何限制的情况下,系统检索PubMed、Scopus、Web of Sciences、Embase等数据库及灰色文献,截止到2022年6月。文章筛选和数据提取基于一个预定义的表由两个独立的审稿人。使用乔安娜布里格斯研究所(JBI)工具评估偏倚风险。结果:我们从初步检索中鉴定出2103条记录。经过重复数据删除和筛选,172篇文章被纳入系统评价。总共有229人(52名男性,173名女性,4名未知)被纳入研究。最常见的不良反应是皮肤(32.75%)、肝脏(13.54%)、过敏(8.3%)和神经系统(5.68%)副作用。此外,大多数报道的副作用与自身免疫性疾病或超敏反应有关。结论:GA和IFN β -1a存在多种副作用,可能与药物免疫调节功能或其他注射相关反应有关。
{"title":"Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.","authors":"Mohsen Rastkar, Mahsa Ghajarzadeh, Mohammad Ali Sahraian","doi":"10.18502/cjn.v22i2.13340","DOIUrl":"10.18502/cjn.v22i2.13340","url":null,"abstract":"<p><p><b>Background:</b> Glatiramer acetate (GA) and Interferon (IFN) beta-1a are used as first-line disease-modifying treatments for multiple sclerosis (MS). In this systematic review, we summarized case reports and case series of adverse side effects of GA and IFN beta-1a in MS patients. <b>Methods:</b> Without any restrictions, PubMed, Scopus, Web of Sciences, and Embase databases, and gray literature were systemically searched until June 2022. Articles were screened and data were extracted based on a predefined table by two independent reviewers. The risk of bias was assessed using the Joanna Briggs Institute (JBI) tool. <b>Results:</b> We identified 2103 records from the preliminary search. After deduplication and screening, 172 articles were included in the systematic review. In total, 229 individuals (52 men, 173 women, and 4 unknown) were included in the study. The most common adverse events were cutaneous (32.75%), hepatic (13.54%), allergic (8.3%), and neurological (5.68%) side effects. Furthermore, most reported side effects were related to autoimmune diseases or hypersensitivity reactions. <b>Conclusion:</b> GA and IFN beta-1a are associated with several side effects which may be related to the immunomodulatory function of medication or other injection-related reactions.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"115-136"},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45412666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of dietary patterns with migraine: A matched case-control study. 饮食模式与偏头痛的相关性:一项匹配的病例对照研究
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13333
Fahimeh Martami, Mansoureh Togha, Mostafa Qorbani, Donya Shahamati, Zhaleh Salami, Sakineh Shab-Bidar

Background: Little is known about the association between dietary patterns and odds of migraine. We aimed to investigate the association between posteriori dietary patterns and migraine odds and migraine-related outcomes using principal component analysis (PCA). Methods: A total of 500 participants enrolled in this age- and sex-matched case-control study. Subjects in the case group were migraine patients who were diagnosed by a neurologist (n = 250) and subjects in the control group were healthy individuals (n = 250). Dietary intake was assessed using a 168-item semi-quantitative Food Frequency Questionnaire (FFQ). Extraction of dietary patterns was performed via PCA. Information on the wide range of covariates and migraine-related outcomes were collected. Results: The 2 major dietary patterns of the "Western diet" and "prudent diet" were extracted using PCA. Those who were in the highest quartile of the prudent diet had the lowest odds of migraine in the fully adjusted model [odds ratio (OR) = 0.10; 95% confidence interval (CI): 0.04-0.21]. Additionally, higher adherence to the Western diet was positively associated with migraine odds (P ˂ 0.001) and this association remained significant and even increased after adjusting a wide range of confounders. Among migraine sufferers, those who had the highest score on the Western diet, had significantly higher attack frequency compared to the patients in the first quartile (15.4 ± 8.9 vs. 12.3 ± 8.6; P = 0.004). Conclusion: The finding of a significant association between the 2 extracted dietary patterns and migraine odds highlights the possible role of diet in both the prevention and stimulation of migraine.

背景:人们对饮食模式和偏头痛发病率之间的关系知之甚少。我们的目的是利用主成分分析(PCA)研究后验饮食模式与偏头痛发病率和偏头痛相关结局之间的关系。方法:共有500名参与者参加了这项年龄和性别匹配的病例对照研究。病例组为经神经科医生诊断的偏头痛患者(n = 250),对照组为健康个体(n = 250)。膳食摄入量评估采用168项半定量食物频率问卷(FFQ)。通过PCA提取饮食模式。收集了广泛的协变量和偏头痛相关结果的信息。结果:采用主成分分析法提取了“西式饮食”和“谨慎饮食”两种主要饮食模式。在完全调整的模型中,那些处于最高四分位数的谨慎饮食者患偏头痛的几率最低[优势比(OR) = 0.10;95%置信区间(CI): 0.04-0.21]。此外,坚持西方饮食与偏头痛的几率呈正相关(P值小于0.001),这种关联仍然显著,甚至在调整了一系列混杂因素后还增加了。在偏头痛患者中,西方饮食得分最高的患者发作频率显著高于第一个四分位数的患者(15.4±8.9比12.3±8.6;P = 0.004)。结论:两种提取的饮食模式与偏头痛发病率之间的显著关联的发现强调了饮食在预防和刺激偏头痛方面的可能作用。
{"title":"Association of dietary patterns with migraine: A matched case-control study.","authors":"Fahimeh Martami, Mansoureh Togha, Mostafa Qorbani, Donya Shahamati, Zhaleh Salami, Sakineh Shab-Bidar","doi":"10.18502/cjn.v22i2.13333","DOIUrl":"10.18502/cjn.v22i2.13333","url":null,"abstract":"<p><p><b>Background:</b> Little is known about the association between dietary patterns and odds of migraine. We aimed to investigate the association between posteriori dietary patterns and migraine odds and migraine-related outcomes using principal component analysis (PCA). <b>Methods:</b> A total of 500 participants enrolled in this age- and sex-matched case-control study. Subjects in the case group were migraine patients who were diagnosed by a neurologist (n = 250) and subjects in the control group were healthy individuals (n = 250). Dietary intake was assessed using a 168-item semi-quantitative Food Frequency Questionnaire (FFQ). Extraction of dietary patterns was performed via PCA. Information on the wide range of covariates and migraine-related outcomes were collected. <b>Results:</b> The 2 major dietary patterns of the \"Western diet\" and \"prudent diet\" were extracted using PCA. Those who were in the highest quartile of the prudent diet had the lowest odds of migraine in the fully adjusted model [odds ratio (OR) = 0.10; 95% confidence interval (CI): 0.04-0.21]. Additionally, higher adherence to the Western diet was positively associated with migraine odds (P ˂ 0.001) and this association remained significant and even increased after adjusting a wide range of confounders. Among migraine sufferers, those who had the highest score on the Western diet, had significantly higher attack frequency compared to the patients in the first quartile (15.4 ± 8.9 vs. 12.3 ± 8.6; P = 0.004). <b>Conclusion:</b> The finding of a significant association between the 2 extracted dietary patterns and migraine odds highlights the possible role of diet in both the prevention and stimulation of migraine.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"87-95"},"PeriodicalIF":0.5,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45904394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iranian specialists' approach to surgery in patients with multiple sclerosis. 伊朗专家对多发性硬化症患者的手术方法
IF 0.7 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13336
Fereshteh Ghadiri, Zahra Ebadi, Elnaz Asadollahzadeh, Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Hora Heidari, Zohreh Abna, Marzieh Aboutorabi, Iman Adibi, Seyed Mohammad Baghbanian, Sepideh Paybast, Maryam Poursadeghfard, Samaneh Hosseini, Sareh Shahmohammadi, Mehran Ghaffari, Hamidreza Ghalyanchi-Langroodi, Masoud Ghiasian, Hoda Kamali, Ebrahim Kouchaki, Farzad Mahrabi, Ehsan Mohammadianinejad, Mohammad Ali Nahayati, Abdorreza Naser Moghadasi

Background: Data on perioperative risk stratification in patients with multiple sclerosis (MS) are limited. In this regard, the present study was conducted to investigate Iranian specialists' approach to surgical counseling for patients with MS (PwMS). Methods: 21 MS specialists were asked about 11 case scenarios with different MS disease statuses, disease-modifying therapies (DMTs), and urgency of the operation. The reasons for refusing surgery or factors that have to be considered before surgery were studied. Results: Overall, Fleiss Kappa was estimated to be 0.091 [95% confidence interval (CI): 0.090-0.093, P < 0.001] indicating a very poor level of agreement among responders. Conclusion: PwMS face surgery for various reasons. Risk assessment of surgery, the effect of various drugs such as anesthetics and DMT on patients, as well as many other aspects of MS are issues challenging the practitioners. Clarifying the various dimensions of these issues requires further research.

背景:多发性硬化症(MS)患者围手术期风险分层的数据有限。在这方面,本研究旨在调查伊朗专家为多发性硬化症患者提供手术咨询的方法。方法:21名MS专家被问及11种不同MS疾病状态、疾病改良疗法(DMTs)和手术紧迫性的病例场景。研究了拒绝手术的原因或手术前必须考虑的因素。结果:总体而言,Fleiss-Kappa估计为0.091[95%置信区间(CI):0.090-0.093,P<0.001],表明应答者之间的一致性非常差。结论:PwMS面部手术的原因多种多样。手术的风险评估、麻醉剂和DMT等各种药物对患者的影响,以及MS的许多其他方面,都是对从业者提出挑战的问题。澄清这些问题的各个方面需要进一步研究。
{"title":"Iranian specialists' approach to surgery in patients with multiple sclerosis.","authors":"Fereshteh Ghadiri, Zahra Ebadi, Elnaz Asadollahzadeh, Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Hora Heidari, Zohreh Abna, Marzieh Aboutorabi, Iman Adibi, Seyed Mohammad Baghbanian, Sepideh Paybast, Maryam Poursadeghfard, Samaneh Hosseini, Sareh Shahmohammadi, Mehran Ghaffari, Hamidreza Ghalyanchi-Langroodi, Masoud Ghiasian, Hoda Kamali, Ebrahim Kouchaki, Farzad Mahrabi, Ehsan Mohammadianinejad, Mohammad Ali Nahayati, Abdorreza Naser Moghadasi","doi":"10.18502/cjn.v22i2.13336","DOIUrl":"10.18502/cjn.v22i2.13336","url":null,"abstract":"<p><p><b>Background:</b> Data on perioperative risk stratification in patients with multiple sclerosis (MS) are limited. In this regard, the present study was conducted to investigate Iranian specialists' approach to surgical counseling for patients with MS (PwMS). <b>Methods:</b> 21 MS specialists were asked about 11 case scenarios with different MS disease statuses, disease-modifying therapies (DMTs), and urgency of the operation. The reasons for refusing surgery or factors that have to be considered before surgery were studied. <b>Results:</b> Overall, Fleiss Kappa was estimated to be 0.091 [95% confidence interval (CI): 0.090-0.093, P < 0.001] indicating a very poor level of agreement among responders. <b>Conclusion:</b> PwMS face surgery for various reasons. Risk assessment of surgery, the effect of various drugs such as anesthetics and DMT on patients, as well as many other aspects of MS are issues challenging the practitioners. Clarifying the various dimensions of these issues requires further research.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"96-102"},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44709150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Waterpipe and cigarette smoking and drug and alcohol consumption, and the risk of primary progressive multiple sclerosis: A population-based case-control study. 水烟、吸烟、吸毒和饮酒与原发性进行性多发性硬化症的风险:一项基于人群的病例对照研究
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13331
Seyyed Hosein Mortazavi, Abdorreza Naser Moghadasi, Amir Almasi-Hashiani, Mohammad Ali Sahraian, Hooman Goudarzi, Sharareh Eskandarieh

Background: Multiple sclerosis (MS) is a chronic central nervous system disease, and primary progressive multiple sclerosis (PPMS) is one the main types of MS, which has unknown environmental risk factors. The present study was conducted with the aim to identify the association of waterpipe and cigarette smoking, substance abuse, and alcohol consumption with the risk of PPMS development. Methods: A population-based, case-control study was conducted in Tehran, Iran, on 146 PPMS cases and 294 controls. PPMS cases were diagnosed and confirmed by neurologists. Standard random digit dialing was used to select sex-matched healthy control participants from the same source population as the cases. Logistic regression analysis was used to estimate unadjusted and adjusted odds ratios (OR). Results: In total, 440 subjects participated in the study. PPMS was associated with ever smoking cigarettes [OR = 2.48; confidence interval (CI) = 1.44-4.27], and passive smoking (OR = 2.20; CI = 1.34-3.62). However, having ever smoked waterpipe was not significantly associated with PPMS risk (OR = 1.19; CI = 0.62-2.26). Those who had all 3 types of smoking had an accumulative OR that was 10.45 times higher than that in individuals without any type of smoking (OR: 10.45; 95% CI = 3.5-31.2). We did not find any significant association between PPMS risk and substance abuse and alcohol consumption. Conclusion: Cigarette smoking and being exposed to passive smoking are important risk factors for developing PPMS; in addition, the use of 3 types of smoking, showed an OR higher than that in those without any smoking. Considering the global increase in tobacco smoking, this finding emphasizes the importance of interventional programs for the prevention of tobacco smoking.

背景:多发性硬化症(Multiple sclerosis, MS)是一种慢性中枢神经系统疾病,其中原发性进行性多发性硬化症(primary progressive Multiple sclerosis, PPMS)是MS的主要类型之一,其环境危险因素未知。本研究的目的是确定水烟、吸烟、药物滥用和饮酒与PPMS发展风险之间的关系。方法:在伊朗德黑兰进行了一项基于人群的病例对照研究,其中146例PPMS病例和294例对照。PPMS病例由神经科医生诊断和确诊。采用标准随机数字拨号,从与病例相同的来源人群中选择性别匹配的健康对照参与者。采用Logistic回归分析估计未调整和调整的比值比(OR)。结果:共纳入研究对象440人。PPMS与吸烟有关[OR = 2.48;[置信区间(CI) = 1.44-4.27]和被动吸烟(OR = 2.20;Ci = 1.34-3.62)。然而,曾经吸过水烟与PPMS风险没有显著相关性(OR = 1.19;Ci = 0.62-2.26)。三种吸烟方式均吸烟的人的累积OR值是不吸烟人群的10.45倍(OR值:10.45;95% ci = 3.5-31.2)。我们没有发现PPMS风险与药物滥用和酒精消费之间有任何显著关联。结论:吸烟和被动吸烟是诱发PPMS的重要危险因素;此外,有3种吸烟方式者的OR值高于没有吸烟方式者。考虑到全球吸烟人数的增加,这一发现强调了预防吸烟的干预方案的重要性。
{"title":"Waterpipe and cigarette smoking and drug and alcohol consumption, and the risk of primary progressive multiple sclerosis: A population-based case-control study.","authors":"Seyyed Hosein Mortazavi, Abdorreza Naser Moghadasi, Amir Almasi-Hashiani, Mohammad Ali Sahraian, Hooman Goudarzi, Sharareh Eskandarieh","doi":"10.18502/cjn.v22i2.13331","DOIUrl":"10.18502/cjn.v22i2.13331","url":null,"abstract":"<p><p><b>Background:</b> Multiple sclerosis (MS) is a chronic central nervous system disease, and primary progressive multiple sclerosis (PPMS) is one the main types of MS, which has unknown environmental risk factors. The present study was conducted with the aim to identify the association of waterpipe and cigarette smoking, substance abuse, and alcohol consumption with the risk of PPMS development. <b>Methods:</b> A population-based, case-control study was conducted in Tehran, Iran, on 146 PPMS cases and 294 controls. PPMS cases were diagnosed and confirmed by neurologists. Standard random digit dialing was used to select sex-matched healthy control participants from the same source population as the cases. Logistic regression analysis was used to estimate unadjusted and adjusted odds ratios (OR). <b>Results:</b> In total, 440 subjects participated in the study. PPMS was associated with ever smoking cigarettes [OR = 2.48; confidence interval (CI) = 1.44-4.27], and passive smoking (OR = 2.20; CI = 1.34-3.62). However, having ever smoked waterpipe was not significantly associated with PPMS risk (OR = 1.19; CI = 0.62-2.26). Those who had all 3 types of smoking had an accumulative OR that was 10.45 times higher than that in individuals without any type of smoking (OR: 10.45; 95% CI = 3.5-31.2). We did not find any significant association between PPMS risk and substance abuse and alcohol consumption. <b>Conclusion:</b> Cigarette smoking and being exposed to passive smoking are important risk factors for developing PPMS; in addition, the use of 3 types of smoking, showed an OR higher than that in those without any smoking. Considering the global increase in tobacco smoking, this finding emphasizes the importance of interventional programs for the prevention of tobacco smoking.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"72-81"},"PeriodicalIF":0.5,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48672845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Journal of Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1